Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Brand profile · Biotechnology Research
Carina Biotech works in Biotechnology Research, out of Adelaide, South Australia. Ownership is privately held; it publishes at carinabiotech.com. It holds one address on record, all in Australia. The record counts 17 people. Tagged science, research & development and biotechnology. One Australian registration (ABN) is a confirmed match. The latest round on record is Series unknown at US$7.5M. The record links nine similar brands, most of them in Biotechnology Research.
ABN43613276074
| CARINA BIOTECH LIMITED | ABN 43613276074 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Carina Biotech
An Australian clinical stage immunotherapy company established to research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers. Carina are working towards producing broad-spectrum CAR-T therapies that can be used to treat multiple solid cancers yet are patient-specific and result in little, if any, off-cancer damage. Using its proprietary platforms, Carina is also developing technologies to improve access to, and infiltration of, solid cancers, and to enhance CAR-T cell manufacturing.
We are working to…
1. Expand the clinical indications for T cell therapies
2. Improve the commercial viability of T cell therapies by developing supporting technologies that make T cell therapies more effective or economically viable
Headquartered in Adelaide, South Australia, Carina has strong T cell R&D capability across a network of research providers and collaborators including leading scientists at the UniSA, the Women's & Children's Hospital in Adelaide, the University of Adelaide, the Royal Prince Alfred Hospital in NSW and the Seattle Children's Hospital in the United States.
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
| Rounds | 1 |
|---|---|
| Axis | 2016 to 2026 |
| Series unknown · 15 Sep 2023 | US$ 7.5M |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Hiring, headcount and registry-change signals, streamed to members.
Registry-filed capital and financial indicators, standardised by TheGrid.
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Counts only. No names are stored here, and none are served.
One South Australia entity on the ABR. CARINA BIOTECH LIMITED (ABN 43 613 276 074), high confidence.
The record holds 17 counted staff profiles at January 2026, above the self-reported 2–10 band.
One address on record, Australia only. Primary: Level 5, Catherine Helen Spence Building, UniSA City West Campus, Adelaide, South Australia 5000.
One round. Latest 15 September 2023: Series unknown, US$7,500,000.
Eight tags on the brand's own list, among them science, research & development and biotechnology.
33 profiles list Carina Biotech as a peer — 97th percentile in Biotechnology Research. It lists ten peers of its own. Prescient Therapeutics and Imugene Limited list it back.